Price
No data yet.
Social Signal Score
Analyst Ratings
7 analystsRevenue
$15.71M+814.14%Analyst Estimates
Consensus estimates, not results. Via Financial Modeling Prep.
Company Profile
- CEO
- Kevin Hykes
- Sector
- Healthcare
- Industry
- Medical - Devices
- Employees
- 223
- Beta
- 0.76
- Country
- US
- Piotroski score
- 3 / 9 (Weak)
- Altman Z-score
- -8.99
Financials
Revenue
$15.71M+814.1%Net Income
$-14.04MEBITDA
$-12.05MFree Cash Flow
$-8.94MEPS (diluted)
$-0.53Shares Outstanding (diluted)
26.52M+5555.9%Operating Expenses
$26.75MCash & Debt
$64.59MReturn of Capital
$43.0KQuote
Valuation & Ratios
Returns & Efficiency
Revenue & Net Income (Annual)
| Fiscal Year | Revenue | Net Income | EPS |
|---|---|---|---|
| 2025 | $56.65M | $-53.31M | $-2.04 |
| 2024 | $51.29M | $-59.97M | $-2.65 |
| 2023 | $39.30M | $-41.20M | $-1.99 |
| 2022 | $22.47M | $-41.43M | $-2.02 |
| 2021 | $13.04M | $-43.08M | $-2.11 |
| 2020 | $6.05M | $-14.11M | $-0.73 |
| 2019 | $6.26M | $-14.63M | $-0.76 |
Valuation
CVRXhas no positive reported earnings per share, so an earnings-multiple projection can't be built for it. Companies are valued on other measures at this stage — revenue growth, cash burn, or book value — none of which this calculator models.
Signal Score (90d)
50+233.33%Social Signal Score
Mentions (8)
- Newsglobenewswire.com·6d ago·Neutral
…te-Breaking Data and New Clinical Evidence on Barostim at the HFSA Annual Scientific Meeting 2026 MINNEAPOLIS, Sept. 29, 2026 (GLOBE NEWSWIRE) -- CVRx, Inc. (NASDAQ: CVRX), a medical device company focused on developing, manufacturing and commercializing innovative neuromodulation solutions for patients with cardiovascular diseases, announced today the schedule of scientific presentations featuring Barostim at the Heart Failure Society of America (HFSA) Annual Scientific Meeting 2026.
View source ↗ - Newsglobenewswire.com·14d ago·Neutral
CVRx Appoints John Landry as Chief Financial Officer Landry Brings Two Decades of Medtech and Public Company Finance Experience Landry Brings Two Decades of Medtech and Public Company Finance Experience
View source ↗ - Newszacks.com·38d ago·Neutral
CVRx Secures Devoted Health Coverage for Barostim Therapy CVRX secures Devoted Health Medicare Advantage coverage for Barostim, expanding reimbursement access to about 466,000 members across 29 states.
View source ↗ - Newsglobenewswire.com·42d ago·Positive
CVRx Responds to Letter from Pointillist Family Office MINNEAPOLIS, Aug. 25, 2026 (GLOBE NEWSWIRE) -- CVRx, Inc. (NASDAQ: CVRX) ("CVRx"), a commercial-stage medical device company focused on developing, manufacturing and commercializing innovative neuromodulation solutions for patients with cardiovascular diseases, today issued the following statement in response to the public letter to CVRx's Board of Directors from Jorey Chernett at Pointillist Family Office, dated August 24, 2026: The Board o…
View source ↗ - Newsglobenewswire.com·43d ago·Neutral
CVRx Announces Devoted Health Medicare Advantage Coverage Policy for Barostim Therapy MINNEAPOLIS, Aug. 24, 2026 (GLOBE NEWSWIRE) -- CVRx, Inc. (NASDAQ: CVRX) (“CVRx”), a commercial-stage medical device company focused on developing, manufacturing and commercializing innovative neuromodulation solutions for patients with cardiovascular diseases, announced today that Devoted Health has issued a Medicare Advantage coverage policy for Barostim therapy, effective July 17, 2026. Devoted Health, a nat…
View source ↗ - Newsprnewswire.com·43d ago·Neutral
Jorey Chernett, Owner of More than 5.5% of Outstanding Shares of CVRx, Calls on Board to Begin Immediate Process to Pursue Sale of the Company to a Strategic Acquirer Delivers Letter to the CVRx Board Highlighting Significant Value Proposition of Barostim to a Large Medical Device Company with Established Infrastructure to Capitalize on the Product's Market Position BLOOMFIELD HILLS, Mich., Aug. 24, 2026 /PRNewswire/ -- Jorey Chernett, Founder of Pointillist Family Office and beneficial owner of
View source ↗ - Newsmarketbeat.com·54d ago·Positive
CVRx Eyes Barostim Growth as Coverage Gains and BENEFIT-HF Trial Launches CVRx NASDAQ: CVRX outlined its efforts to expand adoption of its Barostim therapy for heart failure patients, emphasizing sales-force execution, payer coverage progress and a large post-market clinical trial during Canaccord Genuity's 46th Annual Growth Conference.
View source ↗ - Newsbusinesswire.com·55d ago·Negative
Securities Fraud Investigation Into CVRx, Inc. (CVRX) Announced – Shareholders Who Lost Money Urged To Contact The Law Offices of Frank R. Cruz LOS ANGELES--(BUSINESS WIRE)--The Law Offices of Frank R. Cruz announces an investigation of CVRx, Inc. (“CVRx” or the “Company”) (NASDAQ: CVRX) on behalf of investors concerning the Company's possible violations of federal securities laws. IF YOU ARE AN INVESTOR WHO LOST MONEY ON CVRX, INC. (CVRX), CLICK HERE TO INQUIRE ABOUT POTENTIALLY PURSUING A CLAI
View source ↗
Earnings
Wed, Nov 4(in 4 weeks)
Consensus estimate $-0.49 per share
Typical surprise -1.0% (median, so one quarter with a near-zero estimate can't distort it)
- Thu, Aug 6$-0.53 vs $-0.52miss
- Mon, May 11$-0.50 vs $-0.51beat
- Thu, Feb 12$-0.46 vs $-0.42miss
- Wed, Nov 5$-0.49 vs $-0.50beat
- Mon, Aug 4$-0.57 vs $-0.52miss
- Thu, May 8$-0.53 vs $-0.56beat
Estimates and results for CVRX via Financial Modeling Prep. Beating consensus says the company cleared the bar analysts set, not that the business grew.
Insider trading
Open-market buys and sells by CVRX officers and directors.
- Bought
- $1.8m
- Sold
- $1.0m
14 trades
15 trades
- Binkowski Brentbought
- Binkowski Brentsold
- Adamson Philip B.sold
- Hykes Kevinsold
- Verrastro Paulsold
- Oasheim Jaredsold
- John Robert Allensold
- Jain Mudit K.bought
71 further Form 4 entries are share awards, option exercises or shares withheld for tax. Those are compensation, not trades, so they are excluded above. Buying is the stronger signal: an insider spends their own money for one reason. Selling has many innocent explanations — tax, diversifying, a house — so it says far less than it appears to. Via SEC filings.
Congress trades
- Richard Blumenthalsenate · CT · disclosed Aug 26, 2026 (49d later)Sell$1,001 - $15,000
Self-reported filings, amounts as brackets. Via Senate/House disclosures.